NEJM Journal Watch Oncology and Hematology Top Stories of 2024

Highlights of the most important research from the past year

Dear Readers,

The past year highlighted the wide application and clinical utility of immunotherapy as a component of systemic therapy across a wide variety of malignancies, both in early- and late-stage disease. Additionally, understanding the mutational makeup of a tumor has informed the use of targeted therapy in aggressive breast cancers and non–small-cell lung cancer. Chimeric antigen receptor T-cell therapy has been shown to positively impact outcome in mantle cell lymphoma. Finally, assessing ferritin levels in blood donors may decrease the risk of iron-deficiency compared with simply assessing hemoglobin levels.

The top NEJM Journal Watch Oncology and Hematology stories for 2024 are:

Sotorasib plus Panitumumab for Mutated KRAS G12C Meta…

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)